Published in Clin Cancer Res on February 20, 2012
Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol (2012) 2.17
For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top. Clin Cancer Res (2012) 2.09
Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clin Cancer Res (2015) 1.80
Biomarkers in Breast Cancer - An Update. Geburtshilfe Frauenheilkd (2012) 1.41
Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol (2015) 1.22
Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol (2013) 1.15
B cell-regulated immune responses in tumor models and cancer patients. Oncoimmunology (2013) 1.10
Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res (2014) 1.09
Immune responses to cancer: are they potential biomarkers of prognosis? Front Oncol (2013) 1.01
Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients. BMC Cancer (2012) 0.97
Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. PLoS One (2014) 0.92
The forgotten tale of immunoglobulin allotypes in cancer risk and treatment. Exp Hematol Oncol (2013) 0.91
Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients. PLoS One (2014) 0.91
A shared transcriptional program in early breast neoplasias despite genetic and clinical distinctions. Genome Biol (2014) 0.91
Characterization of tumor-associated B-cell subsets in patients with colorectal cancer. Oncotarget (2014) 0.89
Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer. J Pathol Transl Med (2015) 0.88
Immunoglobulin kappa C predicts overall survival in node-negative breast cancer. PLoS One (2012) 0.87
B cell regulation of the anti-tumor response and role in carcinogenesis. J Immunother Cancer (2016) 0.86
Highlight report: Validation of prognostic genes in lung cancer. EXCLI J (2014) 0.86
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol (2016) 0.85
Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer. J Ovarian Res (2016) 0.84
Evaluating biomarkers in melanoma. Front Oncol (2015) 0.83
Immunoglobulin kappa chain as an immunologic biomarker of prognosis and chemotherapy response in solid tumors. Oncoimmunology (2012) 0.82
Genetic variants of immunoglobulin γ and κ chains influence humoral immunity to the cancer-testis antigen XAGE-1b (GAGED2a) in patients with non-small cell lung cancer. Clin Exp Immunol (2014) 0.82
Cancer research: from prognostic genes to therapeutic targets. EXCLI J (2014) 0.81
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer (2017) 0.80
A genetic variant of FcγRIIIa is strongly associatedwith humoral immunity to cyclin B1 in African American patients with prostate cancer. Immunogenetics (2012) 0.80
Highlight report: Role of the circadian clock system in breast cancer. EXCLI J (2015) 0.79
Highlights in tumor metabolome research: Choline metabolism influences integrin expression and supports cell attachment. EXCLI J (2014) 0.79
Correlation of immunoglobulin G expression and histological subtype and stage in breast cancer. PLoS One (2013) 0.78
Intratumoral CD8⁺ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer. PLoS One (2014) 0.78
Highlight report: Erroneous sample annotation in a high fraction of publicly available genome-wide expression datasets. EXCLI J (2015) 0.78
JNK-dependent gene regulatory circuitry governs mesenchymal fate. EMBO J (2015) 0.78
Using logistic regression to improve the prognostic value of microarray gene expression data sets: application to early-stage squamous cell carcinoma of the lung and triple negative breast carcinoma. BMC Med Genomics (2014) 0.78
Potential biomarkers in the sera of breast cancer patients from bahawalpur, pakistan. Biomark Cancer (2012) 0.77
Collaboration between tumor-specific CD4+ T cells and B cells in anti-cancer immunity. Oncotarget (2016) 0.77
Endogenous antibody responsiveness to epidermal growth factor receptor is associated with immunoglobulin allotypes and overall survival of patients with glioblastoma. Neuro Oncol (2014) 0.76
Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma. J Gastrointest Oncol (2016) 0.75
Tumor architecture exerts no bias on nuclear grading in breast cancer diagnosis. Virchows Arch (2012) 0.75
EDI3, a key enzyme of choline metabolism controls tumour cell migration. EXCLI J (2012) 0.75
Prognostic signatures of breast cancer: Perou's molecular subtypes and Schmidt's metagenes. EXCLI J (2012) 0.75
Lung and breast cancer research: immunoglobulin Kappa C hits the headlines. EXCLI J (2012) 0.75
From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis. Microarrays (Basel) (2013) 0.75
Transcriptomics in developmental toxicity testing. EXCLI J (2013) 0.75
Highlight report: Predicting late metastasis in breast cancer. EXCLI J (2016) 0.75
Tertiary Lymphoid Structures: An Anti-tumor School for Adaptive Immune Cells and an Antibody Factory to Fight Cancer? Front Immunol (2017) 0.75
Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer. J Cancer Res Clin Oncol (2017) 0.75
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2005) 16.35
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2011) 13.30
Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. Bioinformatics (2006) 11.33
Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med (2014) 10.06
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst (2008) 8.62
Natural history of early, localized prostate cancer. JAMA (2004) 7.44
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2009) 7.21
Interactions between cancer stem cells and their niche govern metastatic colonization. Nature (2011) 6.94
Quality of life after radical prostatectomy or watchful waiting. N Engl J Med (2002) 6.83
Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res (2007) 6.59
The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res (2008) 5.69
Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol (2005) 5.53
Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol (2011) 5.28
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med (2009) 4.94
A new measure for functional similarity of gene products based on Gene Ontology. BMC Bioinformatics (2006) 4.82
The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol (2009) 4.73
Exploiting the mutanome for tumor vaccination. Cancer Res (2012) 4.45
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol (2012) 4.44
Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol (2013) 4.28
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med (2012) 4.24
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell (2011) 3.89
Lung cancer incidence in never smokers. J Clin Oncol (2007) 3.20
Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med (2004) 3.18
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood (2002) 3.00
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res (2010) 2.98
The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer (2002) 2.85
Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial. Eur Urol (2013) 2.84
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res (2011) 2.79
Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol (2011) 2.76
Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol (2006) 2.74
Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res (2005) 2.72
Distribution of coronary artery stenosis after radiation for breast cancer. J Clin Oncol (2011) 2.71
Segmentation-based detection of allelic imbalance and loss-of-heterozygosity in cancer cells using whole genome SNP arrays. Genome Biol (2008) 2.67
Identification of high risk breast-cancer patients by gene expression profiling. Lancet (2002) 2.67
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res (2010) 2.66
Radiomics: the process and the challenges. Magn Reson Imaging (2012) 2.65
Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. Eur Urol (2012) 2.62
Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol (2010) 2.56
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet (2010) 2.56
Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics (2013) 2.53
Prediction and validation of cell alignment along microvessels as order principle to restore tissue architecture in liver regeneration. Proc Natl Acad Sci U S A (2010) 2.50
Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst (2007) 2.49
Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst (2010) 2.45
Transient increase in breast cancer risk after giving birth: postpartum period with the highest risk (Sweden). Cancer Causes Control (2002) 2.39
Distinct SNP combinations confer susceptibility to urinary bladder cancer in smokers and non-smokers. PLoS One (2012) 2.38
Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol (2012) 2.38
Suicide risk in men with prostate-specific antigen-detected early prostate cancer: a nationwide population-based cohort study from PCBaSe Sweden. Eur Urol (2009) 2.37
Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer (2003) 2.37
Breast cancer in young women: poor survival despite intensive treatment. PLoS One (2009) 2.36
Sector resection with or without postoperative radiotherapy for stage I breast cancer: 20-year results of a randomized trial. J Clin Oncol (2014) 2.35
The Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer. Scand J Urol (2013) 2.29
Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol (2012) 2.28
A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res (2011) 2.26
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res (2009) 2.26
Tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer. Eur Urol (2009) 2.22
National comparisons of lung cancer survival in England, Norway and Sweden 2001-2004: differences occur early in follow-up. Thorax (2010) 2.21
Prostate cancer imaging trends after a nationwide effort to discourage inappropriate prostate cancer imaging. J Natl Cancer Inst (2013) 2.20
Socioeconomic conditions, lifestyle factors, and self-rated health among men and women in Sweden. Eur J Public Health (2006) 2.19
A high-resolution transcript profile across the wood-forming meristem of poplar identifies potential regulators of cambial stem cell identity. Plant Cell (2004) 2.19
Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol (2012) 2.17
In situ sequencing for RNA analysis in preserved tissue and cells. Nat Methods (2013) 2.13
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat (2010) 2.12
Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe Sweden. Eur Urol (2011) 2.10
In situ detection of phosphorylated platelet-derived growth factor receptor beta using a generalized proximity ligation method. Mol Cell Proteomics (2007) 2.10
Childbearing and the risk of bladder cancer: a nationwide population-based cohort study. Eur Urol (2013) 2.07
Shift towards pro-inflammatory intestinal bacteria aggravates acute murine colitis via Toll-like receptors 2 and 4. PLoS One (2007) 2.05
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol (2013) 2.02
Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat (2007) 2.01
Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood (2006) 2.00
Characterization of the RNA content of chromatin. Genome Res (2010) 1.99
Occupational exposure to heavy metals: DNA damage induction and DNA repair inhibition prove co-exposures to cadmium, cobalt and lead as more dangerous than hitherto expected. Carcinogenesis (2003) 1.97